Dr. Matt Coffey reports

ONCOLYTICS BIOTECH(TM) APPOINTS PATRICIA S. ANDREWS TO ITS BOARD OF DIRECTORS

Oncolytics Biotech Inc. has appointed Patricia S. Andrews to its board of directors.

"I am pleased to welcome Pat Andrews to our board of directors," said Dr. Matt Coffey, president and chief executive officer of Oncolytics. "Pat's extensive board and executive leadership experience navigating first registrational trials in oncology and completing transformational business development agreements with global pharmaceutical companies makes her a natural fit for Oncolytics. As we begin preparations to initiate pivotal studies with pelareorep in breast and pancreatic cancers and progress partnering discussions, we look forward to benefiting from her insights and strategic and operational experience."

"I am honoured to join the Oncolytics board at this exciting time for the organization as it advances pelareorep toward registrational studies," said Ms. Andrews. "Promising recent results from the Bracelet-1 and Goblet studies suggest that pelareorep has the potential to make an important contribution to cancer care, and I look forward to working with my fellow board members in addition to Dr. Coffey and the executive team to execute Oncolytics' clinical and corporate development plans."

Ms. Andrews is an accomplished biopharmaceutical executive and public company board member with a record of success in corporate strategy, first-in-class and first-for-the-company new product commercializations, and business development. Ms. Andrews currently serves as a director and member of the audit committee at GlycoMimetics. During her tenure, the company planned and initiated its first phase 3 study and is preparing for commercialization.

Ms. Andrews previously served as chief executive officer for Sumitomo Pharma Oncology Inc. (SMP Oncology), where she led the organization through the integration of its multiple predecessor companies. Under her leadership, the organization completed three phase 3 trials and expanded the clinical pipeline from two programs to eight. Prior to SMP Oncology, Ms. Andrews served as chief commercial officer for Incyte and led the organization through the launch preparations and introduction of Jakafi, the company's first commercial product, a novel, first-in-class, first-in-disease agent for the treatment of myelofibrosis. While with Incyte, she also steered landmark licensing arrangements with Novartis and Eli Lilly that were critically important to finance the company's long-term trajectory.

Prior to Incyte, Ms. Andrews spent 17 years with Pfizer, ultimately serving as vice-president and general manager of the U.S. oncology business unit, a $900-million portfolio at the time. Under her leadership, Sutent was launched, becoming the market leader in renal cell carcinoma, and a refreshed positioning of Camptosar led to robust revenue growth after years of declining sales in colorectal cancer. Ms. Andrews is a member of the Boston chapter of the board of advisers for Life Science Cares, a collective impact organization dedicated to fighting poverty in local communities. She earned an MBA from the University of Michigan and her BA from Brown University.

About Oncolytics Biotech Inc.

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in phase 2 studies in breast and pancreatic cancers. It acts by inducing anti-cancer immune responses and promotes an inflamed tumour phenotype -- turning cold tumours hot -- through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances toward registrational studies in metastatic breast cancer and pancreatic cancer.

We seek Safe Harbor.